Benign prostatic hyperplasia (BPH) refers to a condition where the prostate gets enlarged or it could be defined as a noncancerous increase in the size of the prostate gland. Various several different types of prostate laser surgery, such as Holmium laser ablation of the prostate (HoLAP), Holmium laser enucleation of the prostate (HoLEP) and Photoselective vaporization of the prostate (PVP).The benign prostatic hyperplasia (BPH) treatment devices refer to the equipment that are utilized in prostate laser surgery. Various type of prostate laser surgery are performed to treat benign prostatic hyperplasia (BPH) condition.
This report contains market size and forecasts of Laser Benign Prostatic Hyperplasia (BPH) Devices in global, including the following market information:
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Laser Benign Prostatic Hyperplasia (BPH) Devices companies in 2021 (%)
The global Laser Benign Prostatic Hyperplasia (BPH) Devices market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Fixed Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Laser Benign Prostatic Hyperplasia (BPH) Devices include Endo Pharmaceuticals, KARL STORZ, Lumenis, Olympus Winter, Urologix, Boston Scientific Corporation, LISA Laser, ProArc Medical and Urovision-Urotech, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Laser Benign Prostatic Hyperplasia (BPH) Devices manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market Segment Percentages, by Type, 2021 (%)
Fixed
Trolley Mounted
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market Segment Percentages, by Application, 2021 (%)
Ambulatory Surgical Centres (ASC)
Urology Centre
Hospitals
Speciality Clinics
Others
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Laser Benign Prostatic Hyperplasia (BPH) Devices Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Laser Benign Prostatic Hyperplasia (BPH) Devices revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Laser Benign Prostatic Hyperplasia (BPH) Devices revenues share in global market, 2021 (%)
Key companies Laser Benign Prostatic Hyperplasia (BPH) Devices sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Laser Benign Prostatic Hyperplasia (BPH) Devices sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Endo Pharmaceuticals
KARL STORZ
Lumenis
Olympus Winter
Urologix
Boston Scientific Corporation
LISA Laser
ProArc Medical
Urovision-Urotech
Teleflex Incorporated
Richard Wolf
BD
Biolitec
Coloplast Corp